<!DOCTYPE html>
<html lang="en">
<head>
<script async src="https://www.googletagmanager.com/gtag/js?id=G-6H85DH0R8S"></script>
<script>window.dataLayer=window.dataLayer||[];function gtag(){dataLayer.push(arguments)}gtag('js',new Date());gtag('config','G-6H85DH0R8S');</script>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Depression Treatment — Evidence-Based Therapy, Medications & Emerging Options</title>
    <meta name="description" content="Comprehensive guide to depression treatment: CBT, IPT, SSRIs, SNRIs, TMS, ECT, and ketamine. What works, when, and for whom.">
    <link rel="icon" type="image/svg+xml" href="data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 32 32'%3E%3Ctext x='16' y='24' font-family='-apple-system,system-ui,sans-serif' font-weight='800' font-size='16' fill='%230d9488' text-anchor='middle' letter-spacing='-0.5'%3E.md%3C/text%3E%3C/svg%3E">
    <link href="https://fonts.googleapis.com/css2?family=Source+Serif+4:wght@400;500;600;700&family=Inter:wght@400;500;600&display=swap" rel="stylesheet">
    <style>
        :root{--bg-primary:#ffffff;--bg-secondary:#f8fafc;--text-primary:#0f172a;--text-secondary:#475569;--text-muted:#94a3b8;--accent:#0d9488;--accent-dark:#0f766e;--accent-light:#ccfbf1;--border:#e2e8f0;--font-display:'Source Serif 4',Georgia,serif;--font-body:'Inter',-apple-system,sans-serif}
        *{margin:0;padding:0;box-sizing:border-box}
        body{font-family:var(--font-body);background:#fafaf9;color:var(--text-primary);line-height:1.7;font-size:16px}
        header{position:sticky;top:0;z-index:100;background:rgba(255,255,255,0.95);backdrop-filter:blur(10px);border-bottom:1px solid var(--border)}
        .header-inner{max-width:1100px;margin:0 auto;padding:16px 24px;display:flex;justify-content:space-between;align-items:center}
        .logo{font-family:var(--font-display);font-size:22px;font-weight:600;color:var(--text-primary);text-decoration:none}
        .logo span{color:var(--accent)}
        nav{display:flex;gap:32px}
        nav a{color:var(--text-secondary);text-decoration:none;font-size:14px;font-weight:500;transition:color 0.2s}
        nav a:hover{color:var(--accent)}
        .article-hero{padding:120px 24px 48px;max-width:720px;margin:0 auto}
        .breadcrumb{font-size:13px;color:var(--text-muted);margin-bottom:16px}
        .breadcrumb a{color:var(--accent);text-decoration:none}
        h1{font-family:var(--font-display);font-size:clamp(32px,5vw,42px);font-weight:700;line-height:1.2;margin-bottom:16px}
        .article-subtitle{font-size:18px;color:var(--text-secondary)}
        main{max-width:720px;margin:0 auto;padding:48px 24px}
        h2{font-family:var(--font-display);font-size:26px;font-weight:700;margin:48px 0 16px}
        h3{font-family:var(--font-display);font-size:20px;font-weight:600;margin:32px 0 12px}
        p{font-size:17px;color:var(--text-secondary);margin-bottom:16px}
        ul{margin:0 0 16px 24px;color:var(--text-secondary)}
        li{margin-bottom:8px;font-size:16px}
        strong{color:var(--text-primary)}
        .treatment-list{list-style:none;margin:24px 0 0 0;border-top:1px solid var(--border)}
        .treatment-list li{padding:24px 0;border-bottom:1px solid var(--border)}
        .treatment-list h4{font-family:var(--font-display);font-size:18px;font-weight:600;margin-bottom:6px}
        .treatment-list p{font-size:15px;margin-bottom:8px}
        .tag{display:inline-block;font-size:11px;font-weight:600;background:var(--accent-light);color:var(--accent);padding:4px 8px;border-radius:4px;margin-bottom:8px}
        table{width:100%;border-collapse:collapse;margin:24px 0;font-size:15px}
        th,td{padding:12px;text-align:left;border-bottom:1px solid var(--border)}
        th{background:var(--bg-secondary);font-weight:600}
        .callout{background:var(--accent-light);border-left:4px solid var(--accent);border-radius:0 8px 8px 0;padding:16px 20px;margin:24px 0}
        .callout p{font-size:15px;color:var(--text-primary);margin-bottom:0}
        footer{background:var(--bg-secondary);border-top:1px solid var(--border);padding:48px 24px}
        .footer-inner{max-width:1100px;margin:0 auto;display:grid;grid-template-columns:2fr 1fr 1fr 1fr;gap:40px}
        .footer-brand .logo{display:inline-block;margin-bottom:12px}
        .footer-brand p{font-size:14px;color:var(--text-muted)}
        .footer-links h4{font-size:12px;font-weight:600;text-transform:uppercase;margin-bottom:12px}
        .footer-links a{display:block;color:var(--text-muted);text-decoration:none;font-size:14px;margin-bottom:8px}
        .footer-links a:hover{color:var(--accent)}
        .footer-bottom{max-width:1100px;margin:32px auto 0;padding-top:24px;border-top:1px solid var(--border);display:flex;justify-content:space-between;font-size:13px;color:var(--text-muted}}
        @media (max-width:768px){nav{display:none}.footer-inner{grid-template-columns:1fr}}
    </style>
</head>
<body>
    <header>
        <div class="header-inner">
            <a href="/" class="logo">depression<span>.md</span></a>
            <nav>
                <a href="/">Home</a>
                <a href="/depression-overview.html">Overview</a>
                <a href="/blog/">Articles</a>
                <a href="/resources.html">Resources</a>
                <a href="/faq.html">FAQ</a>
            </nav>
        </div>
    </header>

    <div class="article-hero">
        <div class="breadcrumb"><a href="/">Home</a> → Treatment Options</div>
        <h1>Evidence-Based Treatment for Depression</h1>
        <p class="article-subtitle">Psychotherapy, medications, and emerging treatments — what works, when, and for whom.</p>
    </div>

    <main>
        <h2>Overview</h2>
        <p>Depression is highly treatable. Approximately 80-90% of people with depression eventually respond well to treatment. The most effective approaches include psychotherapy, medication, or a combination of both.</p>
        <p>Treatment choice depends on severity, prior treatment history, patient preference, and availability of resources. Mild depression often responds to psychotherapy alone, while moderate-to-severe depression typically benefits from combined therapy and medication.</p>

        <h2>Psychotherapy</h2>
        <p>Evidence-based psychotherapies show large effect sizes comparable to medication for mild-to-moderate depression, with benefits that persist after treatment ends.</p>

        <ul class="treatment-list">
            <li>
                <span class="tag">First-Line</span>
                <h4>Cognitive Behavioral Therapy (CBT)</h4>
                <p>CBT identifies and modifies negative thought patterns and maladaptive behaviors. Structured, goal-oriented, typically 12-16 sessions. Meta-analyses show 50-60% response rates with lasting benefits.</p>
                <p><strong>Core components:</strong> Cognitive restructuring, behavioral activation, problem-solving, relapse prevention.</p>
            </li>
            <li>
                <span class="tag">First-Line</span>
                <h4>Interpersonal Therapy (IPT)</h4>
                <p>Focuses on improving interpersonal relationships and communication. Particularly effective for depression triggered by life transitions, grief, role disputes, or social isolation. Typically 12-16 sessions.</p>
                <p><strong>Targets:</strong> Grief, role transitions, role disputes, interpersonal deficits.</p>
            </li>
            <li>
                <span class="tag">Evidence-Based</span>
                <h4>Behavioral Activation (BA)</h4>
                <p>Increases engagement in rewarding activities to counter avoidance and withdrawal. Simpler than CBT, shown to be equally effective for depression. 8-12 sessions.</p>
                <p><strong>Focus:</strong> Activity scheduling, values-based action, reducing avoidance behaviors.</p>
            </li>
            <li>
                <span class="tag">Adjunctive</span>
                <h4>Mindfulness-Based Cognitive Therapy (MBCT)</h4>
                <p>Combines mindfulness meditation with CBT principles. Particularly effective for preventing relapse in recurrent depression. 8-week group program.</p>
                <p><strong>Relapse reduction:</strong> 43% reduction in relapse risk for those with 3+ prior episodes.</p>
            </li>
        </ul>

        <h2>Antidepressant Medications</h2>
        <p>Medications are most effective for moderate-to-severe depression. Typically take 4-6 weeks for full therapeutic effect. All medication decisions should be made with a prescribing physician.</p>

        <h3>First-Line Medications</h3>
        <table>
            <tr>
                <th>Class</th>
                <th>Examples</th>
                <th>Notes</th>
            </tr>
            <tr>
                <td><strong>SSRIs</strong><br>(Selective Serotonin Reuptake Inhibitors)</td>
                <td>Sertraline (Zoloft)<br>Escitalopram (Lexapro)<br>Fluoxetine (Prozac)</td>
                <td>Most commonly prescribed. Generally well-tolerated. Side effects: nausea, sexual dysfunction, weight changes.</td>
            </tr>
            <tr>
                <td><strong>SNRIs</strong><br>(Serotonin-Norepinephrine Reuptake Inhibitors)</td>
                <td>Venlafaxine (Effexor)<br>Duloxetine (Cymbalta)</td>
                <td>Effective for depression with comorbid pain or anxiety. May cause increased blood pressure at high doses.</td>
            </tr>
        </table>

        <h3>Second-Line & Atypical Antidepressants</h3>
        <ul>
            <li><strong>Bupropion (Wellbutrin)</strong> — Dopamine/norepinephrine reuptake inhibitor. Lower risk of sexual side effects and weight gain. Contraindicated in seizure disorders.</li>
            <li><strong>Mirtazapine (Remeron)</strong> — Sedating, increases appetite. Useful for depression with insomnia and weight loss.</li>
            <li><strong>Trazodone</strong> — Often used off-label for insomnia comorbid with depression.</li>
        </ul>

        <div class="callout">
            <p><strong>Important:</strong> Never stop antidepressants abruptly. Discontinuation should be gradual under medical supervision to avoid withdrawal symptoms. Most people need to continue medication for 6-12 months after remission.</p>
        </div>

        <h2>Emerging & Advanced Treatments</h2>
        <p>For treatment-resistant depression (failure to respond to 2+ adequate medication trials), several advanced options show promise.</p>

        <ul class="treatment-list">
            <li>
                <span class="tag">FDA-Approved</span>
                <h4>Transcranial Magnetic Stimulation (TMS)</h4>
                <p>Non-invasive brain stimulation using magnetic pulses. FDA-approved for treatment-resistant depression. Daily sessions for 4-6 weeks. Response rates 50-60% in treatment-resistant patients.</p>
                <p><strong>Advantages:</strong> Non-invasive, no anesthesia, few side effects (mild headache, scalp discomfort).</p>
            </li>
            <li>
                <span class="tag">FDA-Approved</span>
                <h4>Electroconvulsive Therapy (ECT)</h4>
                <p>Most effective treatment for severe, treatment-resistant, or psychotic depression. 80-90% response rate. Requires anesthesia. Modern ECT has minimal side effects; main concern is temporary memory disruption.</p>
                <p><strong>Indications:</strong> Severe depression, psychotic features, acute suicide risk, catatonia.</p>
            </li>
            <li>
                <span class="tag">FDA-Approved (Nasal Spray)</span>
                <h4>Esketamine (Spravato)</h4>
                <p>Nasal spray ketamine derivative for treatment-resistant depression. Administered in clinical setting with monitoring. Rapid onset (hours to days vs weeks). Requires Risk Evaluation and Mitigation Strategy (REMS) program.</p>
                <p><strong>Mechanism:</strong> NMDA receptor antagonist. Different from traditional antidepressants.</p>
            </li>
            <li>
                <span class="tag">Investigational</span>
                <h4>Psilocybin-Assisted Therapy</h4>
                <p>FDA Breakthrough Therapy designation for treatment-resistant depression. Phase 3 clinical trials showing promising results. Not yet approved for clinical use outside of research settings.</p>
            </li>
        </ul>

        <h2>Lifestyle & Adjunctive Interventions</h2>
        <p>While not sufficient as sole treatment for moderate-to-severe depression, lifestyle changes enhance other treatments and prevent relapse:</p>
        <ul>
            <li><strong>Exercise</strong> — 150 minutes/week of moderate aerobic activity shows antidepressant effects comparable to medication for mild depression.</li>
            <li><strong>Sleep hygiene</strong> — Consistent sleep schedule, limiting screens before bed, creating optimal sleep environment.</li>
            <li><strong>Social connection</strong> — Maintaining relationships, joining support groups, volunteering.</li>
            <li><strong>Nutrition</strong> — Mediterranean diet patterns associated with reduced depression risk.</li>
            <li><strong>Light therapy</strong> — 10,000 lux light box for 30 minutes daily. Particularly effective for seasonal affective disorder.</li>
        </ul>

        <h2>Treatment Selection</h2>
        <table>
            <tr>
                <th>Severity</th>
                <th>Recommended Treatment</th>
            </tr>
            <tr>
                <td><strong>Mild Depression</strong><br>(PHQ-9: 5-9)</td>
                <td>Psychotherapy (CBT or IPT) as first-line. Consider behavioral activation, watchful waiting with support.</td>
            </tr>
            <tr>
                <td><strong>Moderate Depression</strong><br>(PHQ-9: 10-19)</td>
                <td>Psychotherapy or medication, or combination. Choice based on patient preference, prior response, availability.</td>
            </tr>
            <tr>
                <td><strong>Severe Depression</strong><br>(PHQ-9: 20-27)</td>
                <td>Combination therapy (psychotherapy + medication) recommended. Consider psychiatry referral.</td>
            </tr>
            <tr>
                <td><strong>Treatment-Resistant</strong><br>(Failed 2+ trials)</td>
                <td>TMS, ECT, esketamine, medication augmentation, intensive psychotherapy.</td>
            </tr>
        </table>

        <div class="callout" style="background:#fef2f2;border-left-color:#dc2626">
            <p><strong>Crisis Resources:</strong> If you are having thoughts of suicide, call or text 988 (Suicide & Crisis Lifeline) or text HOME to 741741 (Crisis Text Line). Available 24/7.</p>
        </div>
    </main>

    <footer>
        <div class="footer-inner">
            <div class="footer-brand">
                <a href="/" class="logo">depression<span>.md</span></a>
                <p>Evidence-based mental health information, part of the thrive.md network.</p>
            </div>
            <div class="footer-links">
                <h4>Learn</h4>
                <a href="/depression-overview.html">Depression Overview</a>
                <a href="/treatment.html">Treatment Options</a>
                <a href="/faq.html">FAQ</a>
            </div>
            <div class="footer-links">
                <h4>Resources</h4>
                <a href="/resources.html">Crisis Support</a>
                <a href="/resources.html">Find a Therapist</a>
            </div>
            <div class="footer-links">
                <h4>About</h4>
                <a href="https://thrive.md/editorial-policy">Editorial Policy</a>
                <a href="mailto:hello@thrive.md">Contact</a>
            </div>
        </div>
        <div class="footer-bottom">
            <p>© 2026 depression.md</p>
            <p>Privacy · Terms</p>
        </div>
    </footer>
</body>
</html>
